FDA grants orphan drug status to Mustang Bio's brain cancer treatment Jul 7, 2025 08:32AM
Mustang Bio (MBIO) Regains Nasdaq Compliance Mar 5, 2025 04:17PM
Mustang Bio (MBIO) Announces Sale of Fixed Assets and Exit of Facility Feb 27, 2025 04:06PM
Mustang Bio (MBIO) Regains Nasdaq Compliance Feb 11, 2025 04:11PM
Mustang Bio (MBIO) Prices 2.66M Share Offering at $3.01/sh Feb 6, 2025 07:01AM


Jan 14, 2025 08:02AM Mustang Bio (MBIO) Announces 1:50 Reverse Share Split
Nov 12, 2024 08:31AM Mustang Bio (MBIO) Receives Positive Listing Determination from Nasdaq
Nov 7, 2024 08:32AM Mustang Bio (MBIO) Granted FDA Orphan Drug Designation for MB-108
Oct 24, 2024 02:10PM Mustang Bio (MBIO) Announces Exercise of Warrants for $4 Million Gross Proceeds
Jun 20, 2024 08:01AM Mustang Bio (MBIO) Announces 6.13M Share Offering at $0.41/sh
Jun 17, 2024 08:31AM Mustang Bio (MBIO) Reports Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Trial of MB-106